Wegovy reduces heavy drinking in first controlled alcoholism study
Updated
Updated · Bloomberg · Apr 30
Wegovy reduces heavy drinking in first controlled alcoholism study
13 articles · Updated · Bloomberg · Apr 30
After six months, volunteers reported five heavy-drinking days in 30 days, down 12 from baseline, while total alcohol intake and blood markers also improved.
The latest findings add detail to a Danish trial in 108 adults with obesity and alcohol use disorder, where semaglutide cut heavy-drinking days by 41% versus 26% for placebo.
The study, published in The Lancet, suggests GLP-1 medicines could offer a new option for alcohol use disorder beyond existing FDA-approved treatments, while also helping with cravings and weight loss.
A new drug treats alcoholism but is dangerous with alcohol. How can this medical paradox be safely solved for patients?
If a weight-loss drug can curb addiction, could it permanently alter the brain's ability to feel pleasure?
Since your genes may decide if Ozempic works, is a DNA test the future for treating addiction?